What is Wedbush’s Forecast for Geron FY2026 Earnings?

Geron Co. (NASDAQ:GERN) – Research analysts at Wedbush dropped their FY2026 earnings per share (EPS) estimates for Geron in a report issued on Wednesday, February 26th. Wedbush analyst R. Driscoll now anticipates that the biopharmaceutical company will post earnings per share of $0.07 for the year, down from their previous forecast of $0.11. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share.

A number of other equities research analysts have also issued reports on GERN. Scotiabank reduced their target price on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a report on Thursday. HC Wainwright cut Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. Barclays reiterated an “overweight” rating and issued a $4.00 target price (down from $9.00) on shares of Geron in a report on Thursday. B. Riley downgraded Geron from a “buy” rating to a “neutral” rating and cut their price target for the stock from $3.50 to $2.00 in a report on Thursday. Finally, Needham & Company LLC decreased their price objective on Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $5.68.

Geron Stock Up 1.1 %

Shares of GERN opened at $1.76 on Friday. The company’s 50-day simple moving average is $2.97 and its 200-day simple moving average is $3.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 1 year low of $1.46 and a 1 year high of $5.34. The stock has a market capitalization of $1.06 billion, a PE ratio of -5.50 and a beta of 0.53.

Geron (NASDAQ:GERN) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to analyst estimates of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. purchased a new stake in shares of Geron during the 4th quarter worth approximately $28,000. Integrated Wealth Concepts LLC acquired a new stake in Geron during the 4th quarter worth $36,000. GF Fund Management CO. LTD. purchased a new stake in Geron in the fourth quarter valued at $45,000. Readystate Asset Management LP acquired a new position in Geron in the third quarter valued at $58,000. Finally, Rovin Capital UT ADV purchased a new position in shares of Geron during the third quarter worth about $62,000. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.